In a report released today, Justin Kim from Oppenheimer maintained a Buy rating on Apellis Pharmaceuticals (APLS), with a price target of $62.00. The company’s shares closed last Thursday at $45.05.
Kim has an average return of 35.4% when recommending Apellis Pharmaceuticals.
According to TipRanks.com, Kim is ranked #594 out of 7333 analysts.
Currently, the analyst consensus on Apellis Pharmaceuticals is a Strong Buy with an average price target of $66.80, representing a 44.9% upside. In a report released yesterday, Stifel Nicolaus also reiterated a Buy rating on the stock with a $57.00 price target.
See today’s analyst top recommended stocks >>
Apellis Pharmaceuticals’ market cap is currently $3.59B and has a P/E ratio of -5.90. The company has a Price to Book ratio of 34.60.
Based on the recent corporate insider activity of 45 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of APLS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
